Related Experiment Video
Updated: Aug 9, 2026
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
Published on: November 3, 2023
[Central venous access in pediatric patients. A 6-year experience]
J Torramade Ribas1, J L Hernández Lizoáin, C Benito Fernández
1Departamento de Cirugía General, Facultad de Medicina, Universidad de Navarra.
Insights
Central venous access systems (CVAS) provide a safe and effective method for long-term intravenous therapy in children. These devices demonstrate a low complication rate, making them a valuable option for chronically ill pediatric patients.
Area of Science:
- Pediatric Surgery
- Vascular Access Devices
- Intravenous Therapy
Context:
- Increasing use of central venous access systems (CVAS) for chemotherapy and parenteral nutrition.
- Study period: February 1985 to December 1990.
- Implantation of 87 CVAS in 76 pediatric patients (11 months to 15 years).
Purpose:
- To evaluate the safety and efficacy of central venous access systems in pediatric patients.
- To determine complication rates and functional outcomes of CVAS.
- To assess the suitability of CVAS for long-term intravenous therapy in children.
Summary:
- Median function time of 349 days (range: 7-1887 days).
- Overall complication incidence: 0.10 per 10 days.
- Specific complication rates: 0.02 for infection, 0.03 for thrombosis.
- 97.7% of cases had follow-up.
- 19 systems removed due to complications, 11 due to treatment completion.
Impact:
- CVAS offer a long working life and low complication rates.
- These devices are a favorable alternative for chronically ill children needing long-term or cyclic intravenous therapy.
- Supports the continued use and development of CVAS in pediatric care.
Abstract:
The need for an access to the venous system, in order to infuse chemotherapeutic treatments or parenteral nutrition, has increased the number of central venous access systems (CVAS) implanted in the past years. Between February 1985 and December 1990, 87 devices were implanted in 76 patients (from 11 months to 15 years of age), with a median function time of 349 days (range: 7 to 1887 days). The overall incidence of complications was 0.10 per 10 days of catheterization, with complication rates for infection and thrombosis of 0.02 and 0.03, respectively. Nineteen systems were removed because of complications and 11 because of completion of the treatment. Of the cases, 97.7% included a follow-up period. The present study confirms the advantages of these devices, with a long working life and a low complication rate, being a good alternative for chronically ill children requiring long-term and/or cyclic intravenous therapy.
